Significant recruitment milestone achieved in scabies Phase 2 clinical trial

Melbourne,11 September 2024 – Atticus Medical, a leader in pharmaceuticals with a focus on social impact, is proud to announce that we have successfully reached the milestone of enrolling 150 patients in an ongoing Phase 2 clinical trial of moxidectin in people with scabies.

The clinical trial aims to evaluate the safety and efficacy of moxidectin in up to 200 people with scabies and this milestone is a testament to the efforts of our partners at Medicines Development for Global Health, the participating clinical sites, and the patients and their families who have placed their trust in our research.

Atticus Medical's General Manager, Dr John Lambert commented: "This milestone is a significant achievement and a positive indication of the progress we are making. We remain committed to our mission of developing pharmaceuticals that have a meaningful social impact, and we are grateful for the support of our investors and collaborators.

Next steps include completing patient recruitment, conducting detailed data analysis, reporting results and preparing for the final stages of clinical development.Atticus will continue to provide updates on our progress and any significant developments.

About Atticus Medical Pty Ltd

Atticus Medical is dedicated to developing innovative pharmaceutical solutions that address unmet medical needs while ensuring social responsibility. With a strong emphasis on research and development, Atticus Medical aims to make a positive impact on global health through its cutting-edge therapies and commitment to affordable healthcare.

For more information about our clinical trials, please contact us.